Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

455
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
455
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

236
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
236
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

262
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
262
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Inhaled Medications01:23

Inhaled Medications

458
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
458
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

699
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Inflammation in Bronchiectasis.

Drugs·2026
Same author

Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.

Annals of the American Thoracic Society·2026
Same author

Goodbye seems to be the hardest word: long-term macrolide withdrawal in bronchiectasis.

ERJ open research·2026
Same author

Clinical practice guideline for long COVID prevention and treatment.

The European respiratory journal·2026
Same author

Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis.

The Lancet. Respiratory medicine·2026
Same author

Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network.

ERJ open research·2026
Same journal

A hypermetabolic pulmonary lesion in a patient with breast cancer.

Breathe (Sheffield, England)·2026
Same journal

Rigid bronchoscopy is the gold standard management of inhaled foreign bodies in children: myth or maxim?

Breathe (Sheffield, England)·2026
Same journal

The price of immune awakening: bridging knowledge gaps in checkpoint inhibitor-related pneumonitis in lung cancer.

Breathe (Sheffield, England)·2026
Same journal

Where are we with biomarkers in paediatric asthma in 2026?

Breathe (Sheffield, England)·2026
Same journal

Recurrent invasive fungal infection with locally advanced thymoma: diagnostic challenges in complex mediastinal disease.

Breathe (Sheffield, England)·2026
Same journal

Elevated <i>D</i> <sub>LCO</sub> and pulmonary function evolution during treatment in a patient with hyperleukocytosis and leukostasis.

Breathe (Sheffield, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 6, 2025

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
04:10

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

858

Precision medicine in bronchiectasis.

Thomas Pembridge1, James D Chalmers1

  • 1Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Breathe (Sheffield, England)
|January 17, 2022
PubMed
Summary
This summary is machine-generated.

Bronchiectasis management needs personalized therapy due to its complex nature. Identifying individual "treatable traits" through endotyping improves patient outcomes by targeting specific causes of airway inflammation and infection.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

556

Related Experiment Videos

Last Updated: Oct 6, 2025

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
04:10

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

858
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

556

Area of Science:

  • Pulmonology
  • Immunology
  • Genetics

Background:

  • Bronchiectasis is a complex lung disease requiring individualized treatment.
  • Symptoms arise from impaired mucociliary clearance, inflammation, and infection.
  • Current treatments aim to improve airway clearance and address inflammation/infection.

Purpose of the Study:

  • To highlight the importance of personalized therapy in bronchiectasis.
  • To introduce the concept of endotyping and treatable traits in bronchiectasis management.
  • To advocate for a holistic, evidence-based approach to improve patient outcomes.

Main Methods:

  • Review of current bronchiectasis pathophysiology and treatment strategies.
  • Discussion of standardized investigations for identifying underlying causes.
  • Exploration of endotyping and treatable traits as emerging concepts.

Main Results:

  • Bronchiectasis heterogeneity necessitates individualized treatment approaches.
  • Endotyping identifies patient subsets with specific underlying biology.
  • Treatable traits enable targeted therapies for improved outcomes.

Conclusions:

  • A treatable traits approach is crucial for effective bronchiectasis management.
  • Endotyping facilitates the development of more precise and efficacious treatments.
  • Future research should focus on identifying and validating treatable traits in bronchiectasis.